Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ: AUTL )

1.930 +0.040 (+2.12%)
Streaming Delayed Price Updated: 11:49 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 202,300
Open 1.940
Bid (Size) 1.920 (43)
Ask (Size) 1.930 (7)
Prev. Close 1.890
Today's Range 1.885 - 1.960
52wk Range 1.680 - 6.625
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire

Performance

YTD
-26.62%
-26.62%
1 Month
+1.05%
+1.05%
3 Month
-28.25%
-28.25%
6 Month
-51.14%
-51.14%
1 Year
-64.78%
-64.78%

More News

Read More
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Via Benzinga
Autolus Therapeutics Provides Business Updates and 2025 Overview
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
From Autolus Therapeutics plc
Via GlobeNewswire
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Via InvestorPlace
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.